Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

This was the stock's third consecutive day of gains.

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $405.27 which represents a slight increase of $8.00 or 2.01% from the prior close of $397.27. The stock opened at $391.87 ...

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corp. (TM) and Vertex Pharmaceuticals Inc. (VRTX), as well as two micro-cap ...